Cargando…

Calgary Normative Study: design of a prospective longitudinal study to characterise potential quantitative MR biomarkers of neurodegeneration over the adult lifespan

INTRODUCTION: A number of MRI methods have been proposed to be useful, quantitative biomarkers of neurodegeneration in ageing. The Calgary Normative Study (CNS) is an ongoing single-centre, prospective, longitudinal study that seeks to develop, test and assess quantitative magnetic resonance (MR) me...

Descripción completa

Detalles Bibliográficos
Autores principales: McCreary, Cheryl R, Salluzzi, Marina, Andersen, Linda B, Gobbi, David, Lauzon, Louis, Saad, Feryal, Smith, Eric E, Frayne, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7430487/
https://www.ncbi.nlm.nih.gov/pubmed/32792445
http://dx.doi.org/10.1136/bmjopen-2020-038120
_version_ 1783571436767543296
author McCreary, Cheryl R
Salluzzi, Marina
Andersen, Linda B
Gobbi, David
Lauzon, Louis
Saad, Feryal
Smith, Eric E
Frayne, Richard
author_facet McCreary, Cheryl R
Salluzzi, Marina
Andersen, Linda B
Gobbi, David
Lauzon, Louis
Saad, Feryal
Smith, Eric E
Frayne, Richard
author_sort McCreary, Cheryl R
collection PubMed
description INTRODUCTION: A number of MRI methods have been proposed to be useful, quantitative biomarkers of neurodegeneration in ageing. The Calgary Normative Study (CNS) is an ongoing single-centre, prospective, longitudinal study that seeks to develop, test and assess quantitative magnetic resonance (MR) methods as potential biomarkers of neurodegeneration. The CNS has three objectives: first and foremost, to evaluate and characterise the dependence of the selected quantitative neuroimaging biomarkers on age over the adult lifespan; second, to evaluate the precision, variability and repeatability of quantitative neuroimaging biomarkers as part of biomarker validation providing proof-of-concept and proof-of-principle; and third, provide a shared repository of normative data for comparison to various disease cohorts. METHODS AND ANALYSIS: Quantitative MR mapping of the brain including longitudinal relaxation time (T1), transverse relaxation time (T2), T2*, magnetic susceptibility (QSM), diffusion and perfusion measurements, as well as morphological assessments are performed. The Montreal Cognitive Assessment (MoCA) and a brief, self-report medical history will be collected. Mixed regression models will be used to characterise changes in quantitative MR biomarker measures over the adult lifespan. In this report, we describe the study design, strategies to recruit and perform changes to the acquisition protocol from inception to 31 December 2018, planned statistical approach and data sharing procedures for the study. ETHICS AND DISSEMINATION: Participants provide signed informed consent. Changes in quantitative MR biomarkers measured over the adult lifespan as well as estimates of measurement variance and repeatability will be disseminated through peer-reviewed scientific publication.
format Online
Article
Text
id pubmed-7430487
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-74304872020-08-24 Calgary Normative Study: design of a prospective longitudinal study to characterise potential quantitative MR biomarkers of neurodegeneration over the adult lifespan McCreary, Cheryl R Salluzzi, Marina Andersen, Linda B Gobbi, David Lauzon, Louis Saad, Feryal Smith, Eric E Frayne, Richard BMJ Open Neurology INTRODUCTION: A number of MRI methods have been proposed to be useful, quantitative biomarkers of neurodegeneration in ageing. The Calgary Normative Study (CNS) is an ongoing single-centre, prospective, longitudinal study that seeks to develop, test and assess quantitative magnetic resonance (MR) methods as potential biomarkers of neurodegeneration. The CNS has three objectives: first and foremost, to evaluate and characterise the dependence of the selected quantitative neuroimaging biomarkers on age over the adult lifespan; second, to evaluate the precision, variability and repeatability of quantitative neuroimaging biomarkers as part of biomarker validation providing proof-of-concept and proof-of-principle; and third, provide a shared repository of normative data for comparison to various disease cohorts. METHODS AND ANALYSIS: Quantitative MR mapping of the brain including longitudinal relaxation time (T1), transverse relaxation time (T2), T2*, magnetic susceptibility (QSM), diffusion and perfusion measurements, as well as morphological assessments are performed. The Montreal Cognitive Assessment (MoCA) and a brief, self-report medical history will be collected. Mixed regression models will be used to characterise changes in quantitative MR biomarker measures over the adult lifespan. In this report, we describe the study design, strategies to recruit and perform changes to the acquisition protocol from inception to 31 December 2018, planned statistical approach and data sharing procedures for the study. ETHICS AND DISSEMINATION: Participants provide signed informed consent. Changes in quantitative MR biomarkers measured over the adult lifespan as well as estimates of measurement variance and repeatability will be disseminated through peer-reviewed scientific publication. BMJ Publishing Group 2020-08-13 /pmc/articles/PMC7430487/ /pubmed/32792445 http://dx.doi.org/10.1136/bmjopen-2020-038120 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Neurology
McCreary, Cheryl R
Salluzzi, Marina
Andersen, Linda B
Gobbi, David
Lauzon, Louis
Saad, Feryal
Smith, Eric E
Frayne, Richard
Calgary Normative Study: design of a prospective longitudinal study to characterise potential quantitative MR biomarkers of neurodegeneration over the adult lifespan
title Calgary Normative Study: design of a prospective longitudinal study to characterise potential quantitative MR biomarkers of neurodegeneration over the adult lifespan
title_full Calgary Normative Study: design of a prospective longitudinal study to characterise potential quantitative MR biomarkers of neurodegeneration over the adult lifespan
title_fullStr Calgary Normative Study: design of a prospective longitudinal study to characterise potential quantitative MR biomarkers of neurodegeneration over the adult lifespan
title_full_unstemmed Calgary Normative Study: design of a prospective longitudinal study to characterise potential quantitative MR biomarkers of neurodegeneration over the adult lifespan
title_short Calgary Normative Study: design of a prospective longitudinal study to characterise potential quantitative MR biomarkers of neurodegeneration over the adult lifespan
title_sort calgary normative study: design of a prospective longitudinal study to characterise potential quantitative mr biomarkers of neurodegeneration over the adult lifespan
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7430487/
https://www.ncbi.nlm.nih.gov/pubmed/32792445
http://dx.doi.org/10.1136/bmjopen-2020-038120
work_keys_str_mv AT mccrearycherylr calgarynormativestudydesignofaprospectivelongitudinalstudytocharacterisepotentialquantitativemrbiomarkersofneurodegenerationovertheadultlifespan
AT salluzzimarina calgarynormativestudydesignofaprospectivelongitudinalstudytocharacterisepotentialquantitativemrbiomarkersofneurodegenerationovertheadultlifespan
AT andersenlindab calgarynormativestudydesignofaprospectivelongitudinalstudytocharacterisepotentialquantitativemrbiomarkersofneurodegenerationovertheadultlifespan
AT gobbidavid calgarynormativestudydesignofaprospectivelongitudinalstudytocharacterisepotentialquantitativemrbiomarkersofneurodegenerationovertheadultlifespan
AT lauzonlouis calgarynormativestudydesignofaprospectivelongitudinalstudytocharacterisepotentialquantitativemrbiomarkersofneurodegenerationovertheadultlifespan
AT saadferyal calgarynormativestudydesignofaprospectivelongitudinalstudytocharacterisepotentialquantitativemrbiomarkersofneurodegenerationovertheadultlifespan
AT smitherice calgarynormativestudydesignofaprospectivelongitudinalstudytocharacterisepotentialquantitativemrbiomarkersofneurodegenerationovertheadultlifespan
AT fraynerichard calgarynormativestudydesignofaprospectivelongitudinalstudytocharacterisepotentialquantitativemrbiomarkersofneurodegenerationovertheadultlifespan